Triple
T2371116
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Perjeta |
E46091
|
entity |
| Predicate | usedInCombinationWith |
P4791
|
FINISHED |
| Object |
docetaxel
Docetaxel is a chemotherapy drug in the taxane class used to treat various cancers, including breast, lung, prostate, and gastric cancers, by inhibiting cell division.
|
E261833
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: docetaxel | Statement: [Perjeta, usedInCombinationWith, docetaxel]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: docetaxel Context triple: [Perjeta, usedInCombinationWith, docetaxel]
-
A.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
B.
Xeloda
Xeloda is an oral chemotherapy drug (capecitabine) commonly used to treat various cancers, including colorectal and breast cancer.
-
C.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
-
D.
bortezomib
Bortezomib is a proteasome inhibitor chemotherapy drug primarily used in the treatment of multiple myeloma and certain types of lymphoma.
-
E.
Herceptin
Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: docetaxel Triple: [Perjeta, usedInCombinationWith, docetaxel]
Generated description
Docetaxel is a chemotherapy drug in the taxane class used to treat various cancers, including breast, lung, prostate, and gastric cancers, by inhibiting cell division.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: docetaxel Target entity description: Docetaxel is a chemotherapy drug in the taxane class used to treat various cancers, including breast, lung, prostate, and gastric cancers, by inhibiting cell division.
-
A.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
B.
Xeloda
Xeloda is an oral chemotherapy drug (capecitabine) commonly used to treat various cancers, including colorectal and breast cancer.
-
C.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
-
D.
bortezomib
Bortezomib is a proteasome inhibitor chemotherapy drug primarily used in the treatment of multiple myeloma and certain types of lymphoma.
-
E.
Herceptin
Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69a88a145268819083e2736cb835c696 |
completed | March 4, 2026, 7:37 p.m. |
| NER | Named-entity recognition | batch_69abc771302481908540e31abb5aeeba |
completed | March 7, 2026, 6:36 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69aea8a2b1448190b19179cf379993ee |
completed | March 9, 2026, 11:01 a.m. |
| NEDg | Description generation | batch_69aeac6b13ac81909042dddef15ec924 |
completed | March 9, 2026, 11:18 a.m. |
| NED2 | Entity disambiguation (via description) | batch_69aead16b0a881909103e26053cfad84 |
completed | March 9, 2026, 11:20 a.m. |
Created at: March 4, 2026, 7:56 p.m.